Skip to main content
. Author manuscript; available in PMC: 2010 Jun 24.
Published in final edited form as: Aliment Pharmacol Ther. 2008 Aug 1;28(3):289–293. doi: 10.1111/j.1365-2036.2008.03718.x

Table 1. Subject demographics by co-infection status.

Total (n=180) HCV mono-infected (n=136) HCV/HIV coinfected (n=41) Significance OR (95%)

Age in yrs mean (sd) 52.2 (9.0) 53.5 (8.9) 48.1 (8.3) p = 0.00

Gender- males n (%) 129 (69) 89 (65) 32 (78) p = 0.08 0.5 (0.2-1.1)

Race/Ethnicity n (%)
 white 76 (42) 66 (49) 10 (24)
 black 56 (31) 41 (30) 15 (37)
 latino 38 (21) 23 (17) 13 (32)
 other 9 (5) 6 (4) 2 (5) p = 0.04

Past IVDU n (%) 72 (40) 56 (42) 16 (39) p = 0.81 0.9 (0.4-1.9)

Past Substance Use Treatment n (%) 77 (43) 55 (40) 22 (54) p = 0.10 1.8 (0.9-3.7)

Past Psychiatric Treatment n (%) 54 (30) 37 (27) 17 (41) p = 0.07 1.9 (0.9-4.0)

Current Methadone/Buprenorphine Treatment n (%) 11 (6) 10 (7) 1 (2) P = 0.26 0.3 (0.0-2.6)